Top Biotech Stocks Worth Watching – February 07th

Illumina, Thermo Fisher Scientific, Lumentum, Danaher, Vertex Pharmaceuticals, AbbVie, and Cencora are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies in the biotechnology industry that focus on developing and commercializing innovative healthcare products, medications, therapies, and medical technology. These stocks are often associated with higher risk and volatility, but also have the potential for significant growth and financial returns. Investors in biotech stocks closely follow developments in medical research, clinical trials, regulatory approvals, and market trends to assess the future potential of these companies. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Illumina (ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

NASDAQ ILMN traded down $10.19 on Friday, hitting $112.61. 2,722,844 shares of the company were exchanged, compared to its average volume of 1,864,722. The firm has a market capitalization of $17.86 billion, a P/E ratio of -11.33 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company’s 50 day moving average price is $137.37 and its 200-day moving average price is $135.34. Illumina has a twelve month low of $100.08 and a twelve month high of $156.66.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

NYSE:TMO traded down $5.18 during midday trading on Friday, reaching $567.53. The stock had a trading volume of 528,873 shares, compared to its average volume of 2,016,703. The stock has a market capitalization of $217.08 billion, a P/E ratio of 34.36, a PEG ratio of 4.06 and a beta of 0.77. Thermo Fisher Scientific has a 1-year low of $493.30 and a 1-year high of $627.88. The firm’s fifty day simple moving average is $546.51 and its 200-day simple moving average is $571.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Lumentum (LITE)

Lumentum Holdings Inc. manufactures and sells optical and photonic products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company operates through two segments: Optical Communications (OpComms) and Commercial Lasers (Lasers). The OpComms segment offers components, modules, and subsystems that enable the transmission and transport of video, audio, and data over high-capacity fiber optic cables.

Shares of NASDAQ LITE traded down $6.93 during mid-day trading on Friday, hitting $85.74. The company’s stock had a trading volume of 3,089,246 shares, compared to its average volume of 2,313,528. The stock has a market cap of $5.89 billion, a price-to-earnings ratio of -10.32 and a beta of 0.94. Lumentum has a one year low of $38.28 and a one year high of $104.00. The company has a debt-to-equity ratio of 2.87, a current ratio of 5.36 and a quick ratio of 4.04. The company’s fifty day simple moving average is $87.70 and its 200-day simple moving average is $71.27.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of NYSE DHR traded down $2.98 during trading hours on Friday, hitting $207.03. The company had a trading volume of 1,254,987 shares, compared to its average volume of 3,901,817. Danaher has a 1-year low of $207.25 and a 1-year high of $281.70. The stock has a market capitalization of $149.53 billion, a P/E ratio of 39.25, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. The firm’s 50 day moving average is $233.38 and its 200-day moving average is $252.10. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

NASDAQ VRTX traded down $7.35 on Friday, hitting $473.81. The company’s stock had a trading volume of 419,953 shares, compared to its average volume of 1,556,463. The firm has a market cap of $122.02 billion, a PE ratio of -237.90, a PEG ratio of 2.39 and a beta of 0.41. The company’s 50-day moving average is $435.84 and its 200 day moving average is $462.87. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded down $0.63 during midday trading on Friday, reaching $192.34. The company had a trading volume of 924,702 shares, compared to its average volume of 6,136,222. AbbVie has a 52-week low of $153.58 and a 52-week high of $207.32. The company’s 50 day moving average price is $177.38 and its 200 day moving average price is $185.48. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The stock has a market cap of $339.89 billion, a P/E ratio of 80.12, a P/E/G ratio of 1.84 and a beta of 0.58.

Cencora (COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Cencora stock traded up $1.98 during trading hours on Friday, reaching $248.11. The stock had a trading volume of 619,778 shares, compared to its average volume of 1,360,336. Cencora has a 52 week low of $214.77 and a 52 week high of $262.26. The stock has a market cap of $47.95 billion, a PE ratio of 33.01, a PEG ratio of 1.59 and a beta of 0.49. The company has a fifty day simple moving average of $239.08 and a 200-day simple moving average of $236.51. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.